Antihypertensive effects of peroxisome proliferator-activated receptor-{beta}/{delta} activation

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors, which is composed of three members encoded by distinct genes: PPARα, PPARβ/, and PPAR. The biological actions of PPARα and PPAR and their potential as a cardiovascular therapeutic target have been extensively reviewed, whereas the biological actions of PPARβ/ and its effectiveness as a therapeutic target in the treatment of hypertension remain less investigated. Preclinical studies suggest that pharmacological PPARβ/ activation induces antihypertensive effects in direct [spontaneously hypertensive rat (SHR), ANG II, and DOCA-salt] and indirect (dyslipemic and gestational) models of hypertension, associated with end-organ damage protection. This review summarizes mechanistic insights into the antihypertensive effects of PPARβ/ activators, including molecular and functional mechanisms. Pharmacological PPARβ/ activation induces genomic actions including the increase of regulators of G protein-coupled signaling (RGS), acute nongenomic vasodilator effects, as well as the ability to improve the endothelial dysfunction, reduce vascular inflammation, vasoconstrictor responses, and sympathetic outflow from central nervous system. Evidence from clinical trials is also examined. These preclinical and clinical outcomes of PPARβ/ ligands may provide a basis for the development of therapies in combat...
Source: AJP: Heart and Circulatory Physiology - Category: Cardiology Authors: Tags: Call for Papers: Small Vessels Big Problems REVIEW Source Type: research